Clinical, Laboratory, and Molecular Aspects of Factor VII Deficiency

Abstract

Congenital factor VII (FVII) deficiency, the most frequent among the recessively inherited disorders of blood coagulation, is characterized by a wide range of symptoms, from mild mucosal bleeds to life-threatening intracranial hemorrhage. Complete FVII deficiency may cause perinatal lethality. Clinically relevant thresholds of plasma levels are still uncertain, and modest differences in low FVII levels are associated with large differences in clinical phenotypes. Activated FVII (FVIIa) expresses its physiological protease activity only in a complex with tissue factor (TF), which triggers clotting at a very low concentration. Knowledge of the FVIIa–TF complex helps to interpret the clinical findings associated with low FVII activity as compared with other rare bleeding disorders and permits effective management, including prophylaxis, with recombinant FVIIa, which, however, displays a short half-life. Newly devised substitutive and nonsubstitutive treatments, characterized by extended half-life properties, may further improve the quality of life of patients. Genetic diagnosis has been performed in thousands of patients with FVII deficiency, and among the heterogeneous F7 mutations, mostly missense changes, several recurrent variants show geographical distribution and identity by descent. In the general population, common F7 polymorphisms explain a large proportion of FVII level variance in plasma through FVII-lowering effects. Their combination with pathogenic variants may impact on the frequent detection of FVII coagulant levels lower than normal, as well as on mild bleeding conditions. In the twenties of this century, 70 years after the first report of FVII deficiency, more than 200 studies/reports about FVII/FVII deficiency have been published, with thousands of FVII-deficient patients characterized all over the world.

Keywords

coagulation - rare bleeding disorders - factor VII deficiency - FVIIa–TF complex - genetics

Publication History

Article published online:
29 August 2024

• References

• 1 Alexander B, Goldstein R, Landwehr G, Cook CD. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest 1951; 30 (06) 596-608
• 2 World Federation of Hemophilia. Report on the Annual Global Survey 2021
• 3 Abbonizio F, Hassan JH, Riccioni R, Arcieri R, Giampaolo A. National Registry of congenital bleeding disorders (AICE). Report 2017. Istituto Superiore di Sanità. Rapp ISTISAN 2019; III: 54
• 4 Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125 (13) 2052-2061
• 5 Dorgalaleh A, Bahraini M, Shams M. et al. Molecular basis of rare congenital bleeding disorders. Blood Rev 2023; 59: 101029
• 6 Benítez Hidalgo O, Martinez Garcia MF, Corrrales Insa I. et al. VHrare study: prevalence, clinical features and management of severe rare bleeding disorders in a large cohort. eJHaem 2023; 4 (02) 476-482
• 7 Bernardi F, Castaman G, Pinotti M. et al. Mutation pattern in clinically asymptomatic coagulation factor VII deficiency. Hum Mutat 1996; 8 (02) 108-115
• 8 McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EG. Factor VII deficiency and the FVII mutation database. Hum Mutat 2001; 17 (01) 3-17
• 9 Ahmadi SE, Jazebi M, Bahoush G, Baghaipour MR, Ala F, Tabibian S. Congenital combined bleeding disorders, a comprehensive study of a large number of Iranian patients. Clin Appl Thromb Hemost 2021; 27: 1076029621996813
• 10 Halimeh S, Koch L, Kenet G. et al. Genotype-phenotype relationship among 785 unrelated white women with inherited congenital factor VII deficiency: a three-center database study. J Clin Med 2023; 13 (01) 49
• 11 Bernardi F, Dolce A, Pinotti M. et al; International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009; 7 (05) 774-779
• 12 Di Minno MND, Dolce A, Mariani G. STER Study Group. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost 2013; 109 (06) 1051-1059
• 13 Palla R, Siboni SM, Menegatti M, Musallam KM, Peyvandi F. European Network of Rare Bleeding Disorders (EN-RBD) group. Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thromb Res 2016; 148: 128-134
• 14 Saes JL, Verhagen MJA, Meijer K. et al. Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study. Blood Adv 2020; 4 (20) 5025-5034
• 15 Toret E, Ay Y, Karapinar TH, Oymak Y, Kavakli K, Vergin RC. Evaluation of bleeding phenotype of inherited factor VII deficiency in children with a bleeding assessment tool and global assays. J Pediatr Hematol Oncol 2020; 42 (06) e527-e530
• 16 Mariani G, Herrmann FH, Dolce A. et al; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93 (03) 481-487
• 17 McVey JH, Boswell EJ, Takamiya O. et al. Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency. Blood 1998; 92 (03) 920-926
• 18 Peyvandi F, Garagiola I, Menegatti M. Gynecological and obstetrical manifestations of inherited bleeding disorders in women. J Thromb Haemost 2011; 9 (Suppl. 01) 236-245
• 19 Abdul-Kadir R, Gomez K. Reproductive health and hemostatic issues in women and girls with congenital factor VII deficiency: a systematic review. J Thromb Haemost 2022; 20 (12) 2758-2772
• 20 Napolitano M, Di Minno MN, Batorova A. et al. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies. Haemophilia 2016; 22 (05) 752-759
• 21 Hu Y, Repa A, Lisman T. et al. Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII. J Thromb Haemost 2022; 20 (10) 2306-2312
• 22 Herrmann FH, Wulff K, Auerswald G. et al; Greifswald Factor FVII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009; 15 (01) 267-280
• 23 Benlakhl F, Mura T, Schved JK, Giansily-Blaizot M. French Study Group of FVII Deficiency. A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost 2011; 152 (06) 340-346
• 24 Rousseau F, Guillet B, Mura T. et al. Surgery in rare bleeding disorders: the prospective MARACHI study. Res Pract Thromb Haemost 2023; 7 (07) 102199
• 25 Giansily-Blaizot M, Verdier R, Biron-Adréani C. et al; Study Group of FVII Deficiency. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?. Haematologica 2004; 89 (06) 704-709
• 26 Siboni SM, Biguzzi E, Mistretta C, Garagiola I, Peyvandi F. Long-term prophylaxis in severe factor VII deficiency. Haemophilia 2015; 21 (06) 812-819
• 27 Mariani G, Dolce A, Batorova A. et al; STER and the International Factor VII Deficiency Study Groups. Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER. Br J Haematol 2011; 152 (03) 340-346
• 28 Castoldi E, Govers-Riemslag JW, Pinotti M. et al. Coinheritance of factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation. Blood 2003; 102 (12) 4014-4020
• 29 Sevenet PO, Kaczor DA, Depasse F. Factor VII deficiency: from basics to clinical laboratory diagnosis and patient management. Clin Appl Thromb Hemost 2017; 23 (07) 703-710
• 30 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81 (03) 734-744
• 31 Cid AR, Lorenzo JI, Haya S, Montoro JM, Casaña P, Aznar JA. A comparison of FVII:C and FVIIa assays for the monitoring of recombinant factor VIIa treatment. Haemophilia 2001; 7 (01) 39-41
• 32 Branchini A, Rizzotto L, Mariani G. et al. Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency. Haematologica 2012; 97 (05) 705-709
• 33 Greene LA, Goldenberg NA, Simpson ML. et al. Use of global assays to understand clinical phenotype in congenital factor VII deficiency. Haemophilia 2013; 19 (05) 765-772
• 34 Tran HT, Tjønnfjord GE, Holme PA. Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency. Haemophilia 2014; 20 (01) 141-146
• 35 Hedner U, Glazer S, Pingel K. et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2 (8621) 1193
• 36 Morfini M, Batorova A, Mariani G. et al; International FVII [IF7] and Seven Treatment Evaluation Registry [STER] Study Groups. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thromb Haemost 2014; 112 (02) 424-425
• 37 Augustsson C, Persson E. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia. Blood 2014; 124 (20) 3172-3174
• 38 Napolitano M, Giansily-Blaizot M, Dolce A. et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 2013; 98 (04) 538-544
• 39 Shapiro A. The use of prophylaxis in the treatment of rare bleeding disorders. Thromb Res 2020; 196: 590-602
• 40 Kuperman AA, Barg AA, Fruchtman Y. et al. Primary prophylaxis for children with severe congenital factor VII deficiency - clinical and laboratory assessment. Blood Cells Mol Dis 2017; 67: 86-90
• 41 Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost 1978; 39 (03) 675-682
• 42 Mariani G, Herrmann FH, Schulman S. et al; International Factor VII Deficiency Study Group. Thrombosis in inherited factor VII deficiency. J Thromb Haemost 2003; 1 (10) 2153-2158
• 43 Giansily-Blaizot M, Marty S, Chen SW, Pellequer JL, Schved JF. Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous?. Thromb Res 2012; 130 (Suppl. 01) S47-S49
• 44 Marty S, Barro C, Chatelain B. et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia 2008; 14 (03) 564-570
• 45 Mariani G, Konkle AB, Kessler CM. Inhibitors in hemophilias. In Hoffman et al. Hematology, Basic Principles and Practice, 5th ed. Chapter 136. Philadelphia (PA) USA: Elsevier; 2018: 2023-2033
• 46 Ramezanpour N, Zaker F, Biswas A, Dorgalaleh A. Inhibitor in congenital factor VII deficiency; a rare but serious therapeutic challenge-a systematic literature review. J Clin Med 2021; 10 (02) 211
• 47 Branchini A, Baroni M, Pfeiffer C. et al. Coagulation factor VII variants resistant to inhibitory antibodies. Thromb Haemost 2014; 112 (05) 972-980
• 48 Nemerson Y, Esnouf MP. Activation of a proteolytic system by a membrane lipoprotein: mechanism of action of tissue factor. Proc Natl Acad Sci U S A 1973; 70 (02) 310-314
• 49 Gajsiewicz JM, Morrissey JH. Structure function relationship of the interaction between tissue factor and factor VIIa. Semin Thromb Hemost 2015; 41 (07) 682-690
• 50 Banner DW, D'Arcy A, Chène C. et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380 (6569) 41-46
• 51 O'Hara PJ, Grant FJ, Haldeman BA. et al. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci U S A 1987; 84 (15) 5158-5162
• 52 Pavlova A, Preisler B, Driesen J. et al. Congenital combined deficiency of coagulation factors VII and X–different genetic mechanisms. Haemophilia 2015; 21 (03) 386-391
• 53 Chen S, Francioli LC, Goodrich JK. et al; Genome Aggregation Database Consortium. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 2024; 625 (7993) 92-100
• 54 Hagen FS, Gray CL, O'Hara P. et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci U S A 1986; 83 (08) 2412-2416
• 55 Girolami A, Fabris F, Dal Bo Zanon R, Ghiotto G, Burul A. Factor VII Padua: a congenital coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J Lab Clin Med 1978; 91 (03) 387-395
• 56 Giansily-Blaizot M, Rallapalli PM, Perkins SJ. et al. The EAHAD blood coagulation factor VII variant database. Hum Mutat 2020; 41 (07) 1209-1219
• 57 Ferraresi P, Balestra D, Guittard C. et al. Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency. Haematologica 2020; 105 (03) 829-837
• 58 Saes JL, Simons A, de Munnik SA. et al. Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis. Haemophilia 2019; 25 (01) 127-135
• 59 Hausman-Kedem M, Malinger G, Modai S. et al. Monogenic causes of apparently idiopathic perinatal intracranial hemorrhage. Ann Neurol 2021; 89 (04) 813-822
• 60 Arbini AA, Pollak ES, Bayleran JK, High KA, Bauer KA. Severe factor VII deficiency due to a mutation disrupting a hepatocyte nuclear factor 4 binding site in the factor VII promoter. Blood 1997; 89 (01) 176-182
• 61 Giansily-Blaizot M, Lopez E, Viart V. et al. Lethal factor VII deficiency due to novel mutations in the F7 promoter: functional analysis reveals disruption of HNF4 binding site. Thromb Haemost 2012; 108 (02) 277-283
• 62 Marchetti G, Patracchini P, Papacchini M, Ferrati M, Bernardi F. A polymorphism in the 5′ region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet 1993; 90 (05) 575-576
• 63 van 't Hooft FM, Silveira A, Tornvall P. et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 1999; 93 (10) 3432-3441
• 64 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11 (03) 540-546
• 65 Bernardi F, Marchetti G, Pinotti M. et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 1996; 16 (01) 72-76
• 66 Bernardi F, Patracchini P, Gemmati D. et al. Molecular analysis of factor VII deficiency in Italy: a frequent mutation (FVII Lazio) in a repeated intronic region. Hum Genet 1993; 92 (05) 446-450
• 67 Pinotti M, Toso R, Redaelli R, Berrettini M, Marchetti G, Bernardi F. Molecular mechanisms of FVII deficiency: expression of mutations clustered in the IVS7 donor splice site of factor VII gene. Blood 1998; 92 (05) 1646-1651
• 68 Kemball-Cook G, Johnson DJ, Takamiya O, Banner DW, McVey JH, Tuddenham EG. Coagulation factor VII Gln100 –> Arg. Amino acid substitution at the epidermal growth factor 2-protease domain interface results in severely reduced tissue factor binding and procoagulant function. J Biol Chem 1998; 273 (14) 8516-8521
• 69 Toso R, Pinotti M, High KA, Pollak ES, Bernardi F. A frequent human coagulation factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates. Biochem J 2002; 363 (Pt 2): 411-416
• 70 Pshenichnikova O, Selivanova D, Shchemeleva E, Abramova T, Zozulya N, Surin V. Molecular genetic analysis of Russian patients with coagulation factor FVII deficiency. Genes (Basel) 2023; 14 (09) 1767
• 71 Etro D, Pinotti M, Wulff K. et al. The Gly331Ser mutation in factor VII in Europe and the Middle East. Haematologica 2003; 88 (12) 1434-1436
• 72 Lou C, Jiang J, Chen W. et al. Structural and functional characterization of novel F7 mutations identified in Chinese factor VII-deficient patients. Br J Haematol 2023; 202 (03) 623-635
• 73 Sharma R, Jamwal M, Senee HK. et al. Molecular spectrum of inherited FVII deficiency in North India revealed a recurrent variant with a founder effect. Haemophilia 2023; 29 (02) 591-599
• 74 Ravanbod S, Faranoush M, Changi-Ashtiani M, Rokni-Zadeh H, Shahani T. Extensive genetic screening of Iranian Factor FVII-deficient individuals unraveled several novel mutations and postulated founder effects in some cases. Res Pract Thromb Haemost 2022; 7 (01) 100003
• 75 Bernardi F, Liney DL, Patracchini P. et al. Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII. Br J Haematol 1994; 86 (03) 610-618
• 76 Rosen ED, Xu H, Liang Z, Martin JA, Suckow M, Castellino FJ. Generation of genetically-altered mice producing very low levels of coagulation factor VII. Thromb Haemost 2005; 94 (03) 493-497
• 77 Branchini A, Ferrarese M, Lombardi S, Mari R, Bernardi F, Pinotti M. Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency. J Thromb Haemost 2016; 14 (10) 1994-2000
• 78 Rizzotto L, Pinotti M, Pinton P, Rizzuto R, Bernardi F. Intracellular evaluation of ER targeting elucidates a mild form of inherited coagulation deficiency. Mol Med 2006; 12 (7-8): 137-142
• 79 O'Brien DP, Gale KM, Anderson JS. et al. Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood 1991; 78 (01) 132-140
• 80 Toso R, Bernardi F, Tidd T. et al. Factor VII mutant V154G models a zymogen-like form of factor VIIa. Biochem J 2003; 369 (Pt 3): 563-571
• 81 Marchetti G, Caruso P, Lunghi B. et al. Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. J Thromb Haemost 2008; 6 (05) 797-803
• 82 Sorensen AB, Tuneew I, Svensson LA. et al. Beating tissue factor at its own game: design and properties of a soluble tissue factor-independent coagulation factor VIIa. J Biol Chem 2020; 295 (02) 517-528
• 83 Gorkom BL, Holme PA, Joch C. et al. Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency. Hematology 2020; 25 (01) 17-25
• 84 Bern M, Nilsen J, Ferrarese M. et al. An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Sci Transl Med 2020; 12 (565) eabb0580
• 85 Mahlangu J, Paz P, Hardtke M, Aswad F, Schroeder J. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia 2016; 22 (06) 873-879
• 86 Faraj A, Nyberg J, Blouse GE, Knudsen T, Simonsson USH. Subcutaneous marzeptacog alfa (activated) for on-demand treatment of bleeding events in subjects with hemophilia A or B with inhibitors. Clin Pharmacol Ther 2024; 115 (03) 498-505
• 87 Pipe SW, Dunn AL, Young G. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol 2023; 16 (10) 715-729
• 88 Gandhi PS, Zivkovic M, Østergaard H. et al. A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders. Nat Cardiovasc Res 2024; 3: 166-185
• 89 Marcos-Contreras OA, Smith SM, Bellinger DA. et al. Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII. Blood 2016; 127 (05) 565-571
• 90 Pinotti M, Rizzotto L, Chuansumrit A, Mariani G, Bernardi F. International Factor VII Deficiency Study Group. Gentamicin induces sub-therapeutic levels of coagulation factor VII in patients with nonsense mutations. J Thromb Haemost 2006; 4 (08) 1828-1830
• 91 Balestra D, Faella A, Margaritis P. et al. An engineered U1 small nuclear RNA rescues splicing defective coagulation F7 gene expression in mice. J Thromb Haemost 2014; 12 (02) 177-185
• 92 Andersen E, Chollet ME, Baroni M. et al. The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII. Cell Biosci 2019; 9: 69
• 93 Barbon E, Pignani S, Branchini A, Bernardi F, Pinotti M, Bovolenta M. An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes. Sci Rep 2016; 6: 28304
• 94 Andersen E, Chollet ME, Bernardi F. et al. The factor VII variant p.A354V-p.P464Hfs: clinical versus intracellular and biochemical phenotypes induced by chemical chaperones. Appl Sci (Basel) 2021; 11 (13) 5762